Protalix BioTherapeutics (PLX) EBT (2010 - 2026)

Protalix BioTherapeutics' EBT history runs 17 years deep, the most recent figure standing at $21.1 million for Q1 2026.

• On a quarterly basis, EBT rose 666.48% year-over-year to $21.1 million in Q1 2026; TTM through Mar 2026 was $20.3 million, a 109.15% increase from a year earlier, with the FY2025 full-year figure at -$4.6 million, down 152.62% from the prior year.
• EBT advanced to $21.1 million in Q1 2026 per PLX's latest filing, from -$3.7 million in the prior quarter.
• Across five years, EBT topped out at $21.1 million in Q1 2026 and bottomed at -$22.1 million in Q4 2023.
• The 5-year median for EBT is -$2.3 million (2022), against an average of $223882.4.
• Across the five-year window, EBT tumbled 587.01% in 2023 and jumped 666.48% in 2026, its largest moves.
• Year by year, EBT stood at -$3.2 million in 2022, then tumbled by 587.01% to -$22.1 million in 2023, then surged by 153.8% to $11.9 million in 2024, then tumbled by 131.58% to -$3.7 million in 2025, then jumped by 664.21% to $21.1 million in 2026.
• Per Business Quant, the three latest PLX EBT figures stand at $21.1 million (Q1 2026), -$3.7 million (Q4 2025), and $2.2 million (Q3 2025).